HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account

Clinical Expertise

Development and application of novel immunotherapy strategies mainly based on minor Histocompatibility antigens (mHags) after allogeneic stem cell transplantation of patients with myeloma and other hematological malignancies. Within this framework, current focus is on: Identification of novel graft versus malignancy (GvM) associated mHags Therapeutical vaccination of patients with myeloma and other hematological malignancies with dendritic cells loaded with mHag peptides. Development of novel adoptive immunotherapy strategies based on transduction of mHag-specific T cell receptors (TCR) into recall antigen specific T cells. Uncovering the impact of Regulatory T cells in Graft versus Malignancy effect. Uncovering the microenvironment induced immune resistance toward cellular immunotherapy in myeloma patients. Development of myeloma specific immuno-chemotherapy strategies by combining novel immunomodulatory or anti-apoptotic agents with cellular and antibody mediated immune therapy.


Regenerative Medicine Utrecht Rmu: Heidelberglaan, 3584 CJ Utrecht, Netherlands

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology

Follow Us

facebook instagram twitter youtube